Newamsterdam Pharma Company N.V. (NAMS)
NASDAQ:NAMS
Want to see NAMS full AI Analyst Report?
Top Page
NewAmsterdam Pharma Company
(NASDAQ:NAMS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$29.00
▼(-16.38% Downside)
Action:Reiterated
Date:06/04/26
The score is held down primarily by heavy ongoing losses and significant cash burn despite a strong, low-debt balance sheet. Technicals are also weak with the stock trading below major moving averages. Valuation is difficult to support due to negative earnings and no dividend, while recent corporate actions modestly improve flexibility and alignment but do not offset core profitability and cash-flow risks.
Positive Factors
Low leverage / strong balance sheet
Extremely low debt and a large equity base give NewAmsterdam material financial flexibility to fund ongoing clinical programs and absorb trial timing variability. This solvency reduces bankruptcy risk, supports strategic partnerships or licensing negotiations, and lengthens the runway before dilutive capital is required.
Negative Factors
High cash burn
Sustained ~-$142M annual cash outflow materially shortens the company’s financing runway absent new funds or partnerships. Persistent burn forces frequent capital raises or licensing deals, raising dilution and execution risk and constraining long-term planning for multi-year clinical programs unless offset by financings or large collaborations.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Extremely low debt and a large equity base give NewAmsterdam material financial flexibility to fund ongoing clinical programs and absorb trial timing variability. This solvency reduces bankruptcy risk, supports strategic partnerships or licensing negotiations, and lengthens the runway before dilutive capital is required.
Read all positive factors
NewAmsterdam Pharma Company (NAMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.49B
Dividend YieldN/A
Average Volume (3M)1.54M
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth-52.13%
EPS Growth3.91%
CountryUS
Employees68
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.81
Shares Outstanding116,903,980
10 Day Avg. Volume1,037,931
30 Day Avg. Volume1,541,874
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue135.92
Enterprise Value/Gross Profit139.37
Enterprise Value/Ebitda-14.43
Forecast
1Y Price Target
$47.86Price Target Upside38.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.83
Revenue Forecast (FY)$29.28M
NewAmsterdam Pharma Company Business Overview & Revenue Model
Company Description
NewAmsterdam Pharma Company N.V. functions as a clinical-phase biopharmaceutical enterprise, dedicated to enhancing treatment outcomes for patients dealing with metabolic disorders. The company's principal experimental medication, obicetrapib, rep...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, NewAmsterdam Pharma’s ability to generate recurring commercial revenue is limited until it obtains regulatory approvals and launches products. Publicly available sources do not provide sufficient, con...
NewAmsterdam Pharma Company Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
82
Very Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.57M | 22.50M | 45.56M | 14.09M | 102.69M | 0.00 |
| Gross Profit | 22.01M | 22.44M | 45.56M | 14.09M | 102.69M | 0.00 |
| EBITDA | -212.50M | -242.32M | -241.49M | -176.86M | -22.34M | -41.37M |
| Net Income | -212.73M | -203.82M | -241.60M | -176.94M | -22.63M | -41.78M |
Balance Sheet | ||||||
| Total Assets | 732.64M | 769.28M | 864.62M | 347.10M | 478.50M | 67.99M |
| Cash, Cash Equivalents and Short-Term Investments | 636.11M | 636.24M | 834.19M | 340.45M | 467.73M | 60.38M |
| Total Debt | 23.00K | 202.00K | 448.00K | 60.00K | 126.00K | 186.51K |
| Total Liabilities | 67.42M | 85.85M | 107.12M | 58.70M | 48.43M | 11.36M |
| Stockholders Equity | 665.22M | 683.43M | 757.50M | 288.39M | 430.07M | 56.63M |
Cash Flow | ||||||
| Free Cash Flow | -142.19M | -148.03M | -159.24M | -141.24M | 10.44M | -29.54M |
| Operating Cash Flow | -141.92M | -147.78M | -158.56M | -141.22M | 10.66M | -29.51M |
| Investing Cash Flow | -189.28M | -174.92M | -62.85M | -24.00K | -221.00K | -24.00K |
| Financing Cash Flow | 34.07M | 29.52M | 659.51M | 8.91M | 391.90M | 84.70M |
NewAmsterdam Pharma Company Technical Analysis
Negative
34.68
Price Trends
32.95
Negative
32.67
Negative
33.28
Negative
Market Momentum
-1.06
Positive
38.33
Neutral
23.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Negative. The current price of 34.68 is above the 20-day moving average (MA) of 32.24, above the 50-day MA of 32.95, and above the 200-day MA of 33.28, indicating a bearish trend. The MACD of -1.06 indicates Positive momentum. The RSI at 38.33 is Neutral, neither overbought nor oversold. The STOCH value of 23.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAMS.
NewAmsterdam Pharma Company Risk Analysis
NewAmsterdam Pharma Company disclosed 92 risk factors in its most recent earnings report. NewAmsterdam Pharma Company reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NewAmsterdam Pharma Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $4.24B | 57.72 | 13.26% | ― | 56.71% | ― | |
61 Neutral | $5.11B | -12.06 | -49.23% | ― | -100.00% | -46.29% | |
58 Neutral | $7.26B | -14.24 | -68.16% | ― | ― | -1.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $3.49B | -16.98 | -29.80% | ― | -52.13% | 3.91% | |
45 Neutral | $3.53B | -7.43 | -71.31% | ― | ― | -259.98% |
* Healthcare Sector Average
NAMS
NewAmsterdam Pharma Company
29.83
11.62
63.81%
VKTX
Viking Therapeutics
30.38
5.52
22.20%
XENE
Xenon
52.91
21.42
68.02%
KNSA
Kiniksa Pharmaceuticals
55.11
26.39
91.89%
IMVT
Immunovant
35.34
19.87
128.44%
NewAmsterdam Pharma Company Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
NewAmsterdam Shareholders Approve ESPP and Governance Proposals
Positive
Jun 3, 2026
On June 2, 2026, NewAmsterdam Pharma held its annual general meeting of shareholders in Amsterdam, where investors approved the 2026 Employee Stock Purchase Plan allowing eligible staff to buy ordinary shares at a 15% discount to the lower market ...
Executive/Board Changes
NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement
Neutral
Apr 24, 2026
On April 20, 2026, NewAmsterdam Pharma Company N.V. and Chief Accounting Officer Louise Kooij agreed that her employment would end effective August 31, 2026, and on April 24, 2026, they executed a separation agreement detailing her departure terms...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.